Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases

References

• Springer T. A. Adhesion receptors of the immune system. Nature 1990; 346: 425–434
   PubMed Web of Science ®Google Scholar
• Denton K. J., Stretch J. R., Gatter K. C., Harris A. L. A study of adhesion molecules as markers of progression in malignant melanma. Jour. Pathol. 1992; 167: 187–191
   PubMed Web of Science ®Google Scholar
• Natali P., Nicotra M. R., Cavaliere R., Bigotti A., Romano G., Temponi M., Ferrone S. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990; 50: 1271–1278
   PubMed Web of Science ®Google Scholar
• Johnson J. P., Stade B. G., Holzmann B., Schwäble W., Riethmüller G. De novo expression of cell adhesion molecule ICAM-1 in melanoma and increased risk of metastasis. Proc. Nat. Acad. Sci. 1989; 86: 641–644
   PubMed Web of Science ®Google Scholar
• Anichini A., Mortarini R., Supino R., Parmiani G. Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability. Int. Jour. Cancer 1990; 46: 508–515
   PubMed Web of Science ®Google Scholar
• Braakman E., Goedegebuure P. S., Vreugdenhil R. J., Segal D. M., Shaw S., Bolhuis R. L. ICAM-melanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int. Jour. Cancer 1990; 46: 475–480
   PubMed Web of Science ®Google Scholar
• Giavazzi R., Chirivi R. G., Garofalo A., Rambaldi A., Hemingway I., Pigott R., Gearing A. J. Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Res 1992; 52: 2628–2630
   PubMed Web of Science ®Google Scholar
• Kageshita T., Yoshii A., Kimura T., Kuriya N., Ono T., Tsujisaki M., Imai K., Ferrone S. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 1993; 53: 4927–4932
   PubMed Web of Science ®Google Scholar
• Picker L. J., Butcher E. C. Physiological and molecular mechanisms of lymphocyte homing. Annu. Rev. Immunol. 1992; 10: 561–591
   PubMed Web of Science ®Google Scholar
• Martin A., Huber G. K., Davies T. F. Induction of human thyroid cell ICAM-1 (CD54) antigen expression and ICAM-1 mediated lymphocyte binding. Endocrinology 1990; 127: 651–657
   PubMed Web of Science ®Google Scholar
• Isobe M., Yagita H., Okumura K., Ihara A. Specific Acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125–1127
   PubMed Web of Science ®Google Scholar
• Paul L. C., Davidoff A., Benediktsson H. The efficacy of LFA-1 and VLA-4 antibody treatment in rat vascularized cardiac allograft rejection. Transplantation 1993; 55: 1196–1199
   PubMed Web of Science ®Google Scholar
• Berlin P. J., Bacher J. D., Sharrow S. O., Gonzalez C., Gress R. E. Monoclonal antibodies against human T cell adhesion molecules-modulation of immune function in nonhuman primates. Transplantation 1992; 53: 840–849
   PubMed Web of Science ®Google Scholar
• Mauff B. L., Hourmant M., Rongier J. -P., Hira M. Effect of anti LFA-1 (CDIIa) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991; 52: 291–296
   PubMedGoogle Scholar
• Cosmi A. B., Conti D., Delmonico F. L. In Vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J. Immunol. 1990; 144: 4604–4612
   PubMedGoogle Scholar
• Fisher A., Griscelli C., Blance S. Prevention of graft failure by an anti-LFA-1 monoclonal antibody in HLA-mismatched bone marrow transplantation. Lancet 1986; 2: 1058–1061
   PubMedGoogle Scholar
• Anand R., Ma D., Alizadeh H., Comerford S. A., Sambrook J. F., Gething M. J., McLean I., Niederkorn J. Y. Characterization of intraocular tumors arising in transgenic mice. Invest. Ophthalmol. Vis. Sci. 1994; 35: 3533–3539
   PubMedGoogle Scholar
• Ma D., Alizadeh H., Comerford S. A., Gething M. J., Sambrook J. F., Anand R., Niederkorn J. Y. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr. Eye Res. 1994; 13: 361–369
   PubMed Web of Science ®Google Scholar
• Boon T., van Snick J., van Pel A., Uyttenhove C., Marchand M. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. Jour. Exp. Med. 1980; 152: 1184–1193
   PubMedGoogle Scholar
• Knisely T. L., Luckenbach M. W., Fischer B. J., Niederkorn J. Y. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. Jour. Immunol. 1987; 138: 4515–4523
   PubMed Web of Science ®Google Scholar
• Knisely T. L., Niederkorn J. Y. Immunological evaluation of spontaneous regression of an intraocular murine melanoma. Invest. Ophthalmol. Vis. Sci. 1990; 31: 247–257
   PubMedGoogle Scholar
• Niederkorn J. Y., Streilein J. W. Adoptive transfer of immunity to intraocular tumors in mice. Invest. Ophthalmol. Vis. Sci. 1984; 25: 336–342
   PubMedGoogle Scholar
• Takei F. Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (MALA-2). J. Immunol. 1985; 134: 1403–1407
   PubMed Web of Science ®Google Scholar
• Sanchez-Madrid F., Simon P., Thompson S., Springer T. A. Mapping of antigenic and functional epitopes on the α- and β-subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1. J. Exp. Med. 1983; 158: 586–602
   PubMed Web of Science ®Google Scholar
• Benson J. L., Niederkorn J. Y. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber. Immunology 1991; 74: 153–159
   PubMedGoogle Scholar
• Niederkorn J. Y., Knisely T. L., Mayhew E. Immune rejection of metastases arising from intraocular tumors in mice. Invest. Ophthalmol. Vis. Sci. 1986; 27: 1355–1361
   PubMedGoogle Scholar
• Niederkorn J. Y., Knisely T. L. Immunological analysis of a destructive pattern of intraocular tumor resolution. Curr. Eye Res. 1988; 7: 515–526
   PubMed Web of Science ®Google Scholar
• Knisely T. L., Niederkorn J. Y. Emergence of a dominant cytotoxic T lymphocyte (CTL) antitumor effector from tumor infiltrating cells in the anterior chamber of the eye. Cancer Immunol. Immunotherap. 1990; 30: 323–330
   PubMed Web of Science ®Google Scholar
• He Y. -G., Mellon J., Apte R., Niederkorn J. Y. Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 1994; 35: 3218–3225
   PubMedGoogle Scholar
• Li X -Y, Niederkorn J. Y. Effect of anti-ICAM-1 and anti-LFA-1 antibodies on the induction of anterior chamber-associated immune deviation. Regional Immunol 1995, in press
   Google Scholar